MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 60 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $9.651 million which beat the analyst consensus estimate of $7.298 million by 32.24 percent. This is a 7.11 percent decrease over sales of $10.390 million the same period last year.